Biotech

Deal will help the firm add to its line-up of cancer treatments

Enzene said it has built a highly experienced 400-person team under the leadership of Dr. Himanshu Gadgil, CEO at Enzene Biosciences Ltd

Cough syrup maker linked to Uzbekistan deaths halts production; samples of Dok-1 Max sent for analysis

He was earlier the firm's deputy CEO; Outgoing MD Arun Chandavarkar to remain on co Board

CSL Behring's Hemgenix, administered just once, cut the number of bleeding events expected over the course of a year by 54%, a key study of the therapy found

Firm is develop recombinant products in hormones, eyes acquisitions in South East Asia

"We are now getting to 'wet' pathology tests like blood tests etc and we have set up a centre which will have minimal human intervention and maximum automation

Biotechnology major Biocon on Wednesday reported a 71 per cent increase in consolidated net profit at Rs 144 crore for the June quarter on the back of robust growth across business verticals. The company had posted a net profit of Rs 84 crore in the April-June quarter of the previous fiscal. Total revenue rose to Rs 2,217 crore in the first quarter as compared with Rs 1,808 crore in the year-ago period, Biocon said in a regulatory filing. Biocon Executive Chairperson Kiran Mazumdar-Shaw said revenues grew as a result of robust growth in both biosimilar and generics verticals. "Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains," she added. All the company businesses are poised for the next phase of sustainable growth which has been challenged during the two years of the Covid pandemic, Mazumdar-Shaw said.

Jurors found Holmes guilty of four counts of tricking investors into pouring money into what she claimed was a revolutionary testing system

Biomodifying will also receive a percentage of payments received for sublicenses of the licensed IP

Clinical trials of WHO pre-qualified vaccine to start soon; Unicef price is $2 per dose, private market price globally is $8-10; Initial volumes to be imported; India would need 83 mn doses a year

Says India has capacity to produce Covid vaccines for itself and other countries

The deal will also include a potential future milestone payment of up to 300 million euros

Baidu's plans come at a time of increased investment in the healthcare sector since the outbreak of the Covid-19 pandemic

Rossari has reduced the fresh issue component from Rs 150 crore to Rs 50 crore

Spain's Pharma Mar is looking at listing on New York's Nasdaq market, joining a flurry of biotech companies aiming to tap investors' voracious appetite for the sector

Modi holds meeting on agro marketing reforms amid Covid lockdown; stresses on need to protect small farmer

IITs have collectively written to all recruiters asking them to honour their offers

Early Karuna holders saw more than 420 per cent returns since the June IPO at $16 a share

It continues to be the only company from Asia to feature on the prestigious US-based 'Science' magazine's annual 'Science Careers Top 20 Employers' list, since its debut in 2012